Completion of placing of new shares under the general mandate
Filed with HKEX · Stock code 1548 · · 3 pages · English
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. This ann
Genscript Biotech Corporation on 6ix
Earlier from Genscript Biotech
- GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
- GenScript Sets New Benchmark for Responsible Biotech Leadership with 2025 ESG Report
- GenScript and Mimulus Partner to Industrialize DNA-Based Data Storage for the AI Era
- GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
- GenScript Biotech Global Forum, "Scripting Possibilities", Convened AI and Biopharma Leaders in San Francisco
Later from Genscript Biotech
- Next Day Disclosure Return
- Interim report 2026
- Passing away of an independent non-executive director and change in composition of board committees
- List of directors and their role and function
- Announcement pursuant to rule 13.10 of the listing rules
Follow Genscript Biotech into a list and get an email when it puts out news.
Follow Genscript Biotech